ReviewParkinson's disease2017
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease.
Review in Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05677529 (Prodromal and Overt Parkinson's Disease Epidemiological Study in Brazil), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prodromal and Overt Parkinson's Disease Epidemiological Study in Brazil
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review.Clinical interventions in aging · 2020Pooled it
- A Bottom-Up Analysis of the Cost of Illness of Parkinson's Disease in the Netherlands from a Societal Perspective.Movement disorders clinical practice · 2025Article
- IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease - IMMUPARKNET.Open research Europe · 2024Article
- Prevalence and Cost of Care for Parkinson's Disease in Luxembourg: An Analysis of National Healthcare Insurance Data.PharmacoEconomics - open · 2022Article
- The economic burden of Parkinson disease among Medicare beneficiaries.Journal of managed care & specialty pharmacy · 2022Article
- Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.International journal of environmental research and public health · 2022Article
- Multi-Layer Picture of Neurodegenerative Diseases: Lessons from the Use of Big Data through Artificial Intelligence.Journal of personalized medicine · 2021Review
- Methodological considerations in the assessment of direct and indirect costs of back pain: A systematic scoping review.PloS one · 2021Article
- Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities.Frontiers in neurology · 2020Article
- Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies.Parkinson's disease · 2020Article
- State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease.NPJ Parkinson's disease · 2019Article
- Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.Clinical interventions in aging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.